Hyperprogressive Disease in Patients with Non–Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of ¹⁸F-FDG PET/CT

A new pattern of response, so-called hyperprogressive disease (HPD), is emerging during treatment with immune checkpoint inhibitors (ICIs). Our aim was to investigate the prevalence of such a phenomenon and to assess its association with clinical variables and metabolic parameters by ¹⁸F-FDG PET/CT. Methods: Data from 50 patients (34 men and 16 women; median age, 73 y) with non–small cell lung carcinoma treated with ICIs were...